PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Drospirenone→

Drospirenone PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
67392-87-4
Molecular formula
C24H30O3
Molecular weight
366.5 g/mol
Drug class
Synthetic progestogenprogesterone receptor agonist with antimineralocorticoid and antiandrogenic activity
Mechanism of action
Activates progesterone receptors to suppress gonadotropin secretion and ovulation and also antagonises mineralocorticoid and androgen receptors, contributing to antimineralocorticoid and antiandrogenic effects.
Indications / reported uses
  • Component of combined oral contraceptive products for prevention of pregnancy
  • Used in selected hormone therapy combinations to oppose oestrogen effects on the endometrium; drospirenone-only and combination-product indications differ by jurisdiction

Sources: US DailyMed — Drospirenone-containing products · NLM MeSH — Drospirenone · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Drospirenone PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Drospirenone Permitted Daily Exposure (PDE) report (the Drospirenone PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Drospirenone Occupational Exposure Limit (OEL) report (the Drospirenone OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.